Diligence memo · auto-generated · as of July 2, 2026

Semba Biosciences Inc

Semba Biosciences Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Semba Biosciences Inc operates in Biotechnology, based in MADISON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Semba Biosciences Inc has raised $4.5M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.0M on 2018-12-01.

Most recent recorded round closed around 2018-12-01.

Valuation (modeled)modeled

Provath models Semba Biosciences Inc at approximately $133M (range $2.2M–$1.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.87× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 26 months.

Last raise 7.6 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 5.9× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 42% of Biotechnology peers (4293 compared).

Modeled value ranks above 64% of those peers.

Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.